Gerasimos J. Zaharatos

Dr. Gerasimos J. Zaharatos

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2018 in Viruses
Verified
Journal Article
Open access
PDF file
LALara Ajamian
Lara Ajamian
LMLuca Melnychuk
Luca Melnychuk
PJPatrick Jean-Pierre
Patrick Jean-Pierre
GZGerasimos J. Zaharatos
Gerasimos J. Zaharatos
Flagellin’s potential as a vaccine adjuvant has been increasingly explored over the last three decades. Monomeric flagellin proteins are the only known agonists of Toll-like receptor 5 (TLR5). This interaction evokes a pro-inflammatory state that impacts upon both innate and adaptive immunity. While pathogen associated molecular patterns (PAMPs) like flagellin have been used as stand-alone adjuvants that are co-delivered with antigen, some investigators have demonstrated a distinct advantage to incorporating antigen epitopes within the structure of flagellin itself. This approach has been particularly effective in enhancing humoral immune responses. We sought to use flagellin as both scaffold and adjuvant for HIV gp41 with the aim of eliciting antibodies to the membrane proximal external region (MPER). Accordingly, we devised a straightforward step-wise approach to select flagellin-antigen fusion proteins for gene-based vaccine development. Using plasmid DNA vector-based expression in mammalian cells, we demonstrate robust expression of codon-optimized full length and hypervariable region-deleted constructs of Salmonella enterica subsp. enterica serovar Typhi flagellin (FliC). An HIV gp41 derived sequence including the MPER (gp41607–683) was incorporated into various positions of these constructs and the expressed fusion proteins were screened for effective secretion, TLR5 agonist activity and adequate MPER antigenicity. We show that incorporation of gp41607–683 into a FliC-based scaffold significantly augments gp41607–683 immunogenicity in a TLR5 dependent manner and elicits modest MPER-specific humoral responses in a mouse model.

1 January 2023 in Annals of Internal Medicine
Verified
Journal Article
Open access
LHLuke B. Harrison
Luke B. Harrison
GBGeneviève Bergeron
Geneviève Bergeron
GCGeneviève Cadieux
Geneviève Cadieux
HCHugues Charest
Hugues Charest
JFJudith Fafard
Judith Fafard
SBSapha Barkati
Sapha Barkati
A global outbreak of monkeypox occurred beginning in mid-2022 outside of endemic areas. This report characterizes the outbreak of monkeypox in Montréal, the first large outbreak in North America, u... Visual Monkeypox in Montréal. A global outbreak of monkeypox occurred beginning in mid-2022 outside of endemic areas. This report characterizes the outbreak of monkeypox in Montréal, the f... Background: Monkeypox, a viral zoonotic disease, is causing a global outbreak outside of endemic areas. Objective: To characterize the outbreak of monkeypox in Montréal, the first large outbreak in...

9 December 2011 in Vaccine
Verified
Journal Article
Closed access
GZGerasimos J. Zaharatos
Gerasimos J. Zaharatos
JYJian Yu
Jian Yu
CPCraig Pace
Craig Pace
YSYang Song
Yang Song
SVSandhya Vasan
Sandhya Vasan
YHYaoxing Huang
Yaoxing Huang

3 July 2012 in Annals of Medicine
Verified
Journal Article
Closed access
PDF file
GZGerasimos J. Zaharatos
Gerasimos J. Zaharatos
MWMark A. Wainberg
Mark A. Wainberg
A combination of antiretroviral drugs (ARVs) is necessary to achieve sustained virologic suppression of HIV viral load (< 50 copies/mL). Rilpivirine (RPV) is a potent new non-nucleoside reverse transcriptase inhibitor (NNRTI) that has the potential to be part of effective ARV combinations. Here, we review currently available data on RPV from the standpoint of virologic suppression and efficacy, drug-drug interactions safety, and resistance. This review presents data on the results of clinical trials involving RPV. The topics considered include antiviral potency, dosing, clinical utility, drug resistance, toxicity profile, and pharmacokinetics. RPV is a potent new addition to the antiretroviral family of drugs for use in combination therapy in previously untreated HIV-infected patients. However, caution needs to be exercised in administration of RPV to patients who initiated therapy with viral loads > 100,000 viral RNA copies/mL.

6 December 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
YLYves Longtin
Yves Longtin
LPLeighanne O. Parkes
Leighanne O. Parkes
HCHugues Charest
Hugues Charest
SRStacy Rajarison
Stacy Rajarison
GZGerasimos J. Zaharatos
Gerasimos J. Zaharatos
GSGaston De Serres
Gaston De Serres
We performed viral culture of nasopharyngeal specimens in individuals aged 79 and older, infected with severe acute respiratory coronavirus virus 2 (SARS-CoV-2), 10 days after symptom onset. A positive viral culture was obtained in 10 (45%) of 22 participants, including 4 (33%) of 12 individuals with improving symptoms. The results of this small study suggest that infectivity may be prolonged among older individuals.

1 May 2017 in Vaccine
Verified
Journal Article
Closed access
LMLuca Melnychuk
Luca Melnychuk
LALara Ajamian
Lara Ajamian
PJPatrick Jean-Pierre
Patrick Jean-Pierre
JLJiaming Liang
Jiaming Liang
RGRomina Gheorghe
Romina Gheorghe
GZGerasimos J. Zaharatos
Gerasimos J. Zaharatos